Your SlideShare is downloading. ×
Module 10 Dr Blasko-HighRiskPC
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Module 10 Dr Blasko-HighRiskPC

132

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
132
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide
  • This sets the theme for this talk which is multimodality therapy is standard and that surgery is an inferior approac
  • 1 st Group References: 1. Bahn, D et al. Targeted Cryoablation of the Prostate:7-year Outcomes in the Primary Treatment of Prostate Cancer. Urology 2002;60(Supp 2A):3-11. 2. Burri, R et al. Young Men have Equivalent Biochemical Outcomes Compared with Older Men After Treatment with Brachytherapy for Prostate Cancer. Int J Radiat Oncol Bio Phys 2010;77(5):1315-21. 3. (Open) 4. Bittner, N et al. Primary Causes of Death After Permanent Prostate Brachytherapy. Int J Radiat Oncol Bio Phys 2008;72(2):433-440. 5. Boorjian, S et al. Mayo Clinic Validation of the D'Amico Risk Group Classification for Predicting Survival Following Radical Prostatectomy. J Urology 2008;179:1354-1361. 6. Carver, B et al. Long Term Outcome following Radical Prostatectomy in Men with Clinical T3 Prostate Cancer. J Urology 2006;176:564-568. 7. Cohen, J et al. Ten-Year Biochemical Disease Control in Patients with Prostate Cancer Treated with Cryosurgery as Primary Therapy. Urology 2008;71(3):515-518. 8. Critz, F et al. 10-year Disease Survival Rates After Simultaneous Irradiation for Prostate Cancer with a Focus on Calculation Methodology. J Urology 2004;172:2232-2238. 9. Galalae, R et al. Long-term Outcome by Risk Factors Using Conformal High-Dose-Rate Brachytherapy (HDR-BT) Boost with or without Neoadjuvant Androgen Suppression for Localized Prostate Cancer . Int J Radiat Oncol Bio Phys 2004;58(4):1048-1055. 10. Kollmeier, M et al. Biochemical Outcomes After Prostate Brachytherapy with 5-year Minimal follow-up: Importance of patient Selection and implant Quality. Int J Radiat Oncol Bio Phys 2003;57(3):645-653. 11. Kuban, D et al. Long-Term Multi-Institutional Analysis of Stage T1-T2 Prostate Cancer Treated with Radiotherapy in the PSA Era. Int J Radiat Oncol Biol Phys 2003;57(4):915-928.(PSA:4-10,GS:2-6,>70 Gy) 12. Kuban, D et al. Long-Term Results of the MD Anderson Randomized Dose-Escalation Trial for Prostate Cancer. Int J Radiat Oncol Bio Phys 2008;70(1):67-74. 13. (Open) 14. (Open) 15. Loeb, S et al. Intermediate-term potency, continence & survival outcomes of radical prostatectomy for clinically high-risk or locally advanced prostate cancer . Urology 2007;69(6):1170-1175. 16. Merrick, G et al. A ndrogen deprivation therapy does not impact cause specific overall survival after permanent prostate brachytherapy. Int J Radiat Oncol Bio Phys 2006;65(3):669-77. (EBRT, Seeds, ADT) 17. Merrick, G et al. Androgen deprivation therapy does not impact cause specific overall survival after permanent prostate brachytherapy. Int j Radiat Oncol Bio Phys 2006;65(3):669-77. (EBRT & Seeds) 18. Merrick, G et al. Prognostic Significance of Perineural Invasion on Biochemical Progression-free Survival after Prostate Brachytherapy . Urology 2005;66(5):1048-1053. 19. Merrick, G et al. Impact of Supplemental External Beam Radiotherapy and/or Androgen Deprivation Therapy on Biochemical Outcome After Permanent Prostate Brachytherapy. Int J Radiat Oncol Bio Phys 2005;61(1):32-43. (EBRT & Seeds) 20. Merrick, G et al. Impact of Supplemental External Beam Radiotherapy and/or Androgen Deprivation Therapy on Biochemical Outcome After Permanent Prostate Brachytherapy. Int J Radiat Oncol Bio Phys 2005;61(1):32-43. (EBRT, Seeds, ADT) 21. Mian, B et al . Outcome of Patients w/ Gleason score 8 or Higher Prostate Cancer following Radical Prostatectomy alone . J Urology 2002;167:1675-1680. 22. Pellizzon, A et al . The Relationship Between the Biochemical Control Outcomes and the Quality of Planning of HDR as a Boost to External Beam Radiotherapy for locally and locally advanced Prostate Cancer using the RTOG-ASTRO Phoenix definition. Int J Med Sci 2008;5:113-120. 23. Stokes, S et al. Comparison of biochemical disease-free survival of patients with localized carcinoma of the prostate undergoing radical prostatectomy, transperineal ultrasound-guided radioactive seed implantation, or definitive external beam irradiation Int J Radiat Oncol Bio Phys 2000;47(1):129-136. (EBRT) 24. Potters, L et al. 12-Year Outcomes Following Permanent Prostate Brachytherapy in Patients With Clinically Localized Prostate Cancer. J Urology 2005;173:1562-1566. 25. Stokes, S et al. Comparison of biochemical disease-free survival of patients with localized carcinoma of the prostate undergoing radical prostatectomy, transperineal ultrasound-guided radioactive seed implantation, or definitive external beam irradiation Int J Radiat Oncol Bio Phys 2000;47(1):129-136. (RP) 26. Sylvester, J et al. Ten Year Biochemical Relapse Free Survival After External Beam Radiation and Brachytherapy for Localized Prostate Cancer: The Seattle Experience. Int J Radiat Oncol Bio Phys 2003;57(4):944-952. 27. (Open) 28. (Open) 29. Thames, H et al. Increasing External Beam Dose for T1-T2 Prostate Cancer: Effect on Risk Groups. Int J Radiat Oncol Bio Phys 2006; 65(4):975-981. 30. Ward, J et al. Radical Prostatectomy for Clinically Advanced (cT3) Prostate Cancer since the advent of PSA testing: 15 year outcome. BJU Int 2005; 95:751-6. 31. Zelefsky, M et al. Multi-Institutional Analysis of Long-Term Outcome for T1-T2 Prostate Cancer Treated with Permanent Seed Implantation. Int J Radiat Oncol Bio Phys 2007;67(2):327-333. 32. Zelefsky, M et al. Long Term Outcome of High Dose Intensity Modulated Radiation Therapy for Patients With Clinically Localized Prostate Cancer. J Urology 2006;176:1415-19. (81 Gy) 33. Zelefsky, M et al. Long-term Results of Conformal Radiotherapy for prostate Cancer: Impact of Dose Escalation in Biochemical Tumor control and distant Metastases-free Survival Outcomes. Int j Radiat Oncol Bio Phys 2008;71(4):1028-33. (81 Gy) 34. Zelefsky, M et al. Long-term Results of Conformal Radiotherapy for prostate Cancer: Impact of Dose Escalation in Biochemical Tumor Control and distant Metastases-free Survival Outcomes. Int j Radiat Oncol bio Phys 2008;71(4):1028-33. (86 Gy) 35. Zelefsky, M et al. High Dose Radiation Delivered by Intensity Modulated Conformal Radiotherapy Improves the Outcome of Localized Prostate Cancer. J Urology 2001;166:876-881. (75 Gy) 36. Zelefsky, M et al. High Dose Radiation Delivered by Intensity Modulated Conformal Radiotherapy Improves the Outcome of Localized Prostate Cancer. J Urology 2001;166:876-881. (81 Gy) 37. Dattoli, M et al. Long-term Outcomes After Treatment with Brachytherapy and Supplemental Conformal Radiation for Prostate Cancer Patients Having Intermediate and High-Risk Features. Cancer 2007;110(3):551-555. 38. Moyad, M et al. Statins, especially Atorvastatin, may Favorable Influence Clinical Presentation and Biochemical Progression-free Survival after Brachytherapy for Clinically Localized Prostate Cancer. Urology 2005;66(6):1150-1154. 39. Zelefsky, M et al . Long Term Outcome Following Three dimensional Conformal/IMRT for Clinical Stage T3 Prostate Cancer. Eurr Urol 2008; 53:1172-79. 40. (Open) 41. Galalae R et al. Hypofractionated Conformal HDR Brachytherapy in Hormone Naïve Men with Localized Prostate Cancer . Strahlenther Onkol 2006;182(3):135-141. 42. Demanes, DJ et al. Excellent Results from High Dose Rate Brachytherapy and External Beam Radiation Therapy for Prostate Cancer are Not Imroved by Androgen Deprivation. Amer J Clin Oncol 2009;32(4):342-347. 43. Stock, R et al. Outcomes for patients with High-Grade Prostate Cancer Treated with a Combination of Brachytherapy, EBRT and Hormone therapy. BJU Int 2009;104:1631-1636. 44. Stone, N et al . Local Control following Permanent Prostate Brachytherapy: Effect of High Biologically Effective Dose on Biopsy Results and Oncologic Outcomes. Int J Radiat Oncol Bio Phys 2010;7 6(2):355-360. 45. Bittner, N et al. Whole Pelvis Radiotherapy in Combination with Interstitial Brachytherapy: Does Coverage of the Pelvic Lymph Nodes Improve Treatment Outcome in High Risk Prostate Cancer? Int J Radiat Oncol Bio Phys 2010;76(4):1078-1084. 46. Rubio-Briones, J et al . Metastatic Progression, Cancer Specific Mortality and Need for Secondary Treatments in Patients with Clinically High Risk Prostate Cancer Treated Initially with Radical Prostatectomy. Actas Urologicas Esanolas 2010; 34(7):610-617. 47. Dattoli, M et al . Long Term Outcomes for Patients with Prostate Cancer Having Intermediate and High Risk Disease, Treated with Combination External Beam Irradiation and Brachytherapy. J Oncology 2010;2010(Article Id 471375):6 pages. 48. Menon, M et al . Biochemical Recurrence Following Robot Assisted Radical Prostatectomy: Analysis of 1384 patients with a median 5 year follow-up. Eurr Urol 2010;58:838-46. 49. Pierorazio, P et al. Long Term Survival after Radical Prostatectomy for Men with High Gleason Sum in Pathologic Specimen. Urology 2010;76(3):715-21. 101. Deger, S et al . (Germany) High Dose Rate (HDR) Brachytherapy with Conformal Radiation Therapy for Localized Prostate Cancer. Eurr Urology 2005;47:441-448. 102. Magheli A et al . (Johns Hopkins) Importance of Tumor Location in Patients with High Preoperative PSA Levels ( greater than 20 ng/ml treated with Radical Prostatectomy . J Urology 2007;178:1311-15. 103. Kupelian P, et al. Improved Biochemical Relapse-Free Survival With Increased Radiation Doses in Patients With Localized Prostate Cancer: The Combined Experience of Nine Institutions in 1994 and 1995. Int J Radiat Oncol Bio Phys 2005;61(2):415-419. 104. Sylvester, J et al. 15-Year Biochemical Relapse Free Survival in Clinical Stage T1-T3 Prostate Cancer Following Combined External Beam Radiotherapy and Brachytherapy: Seattle Experience. Int J Radiat Oncol Bio Phys 2007;67(1):57-64. 105. Hinnen, K et al. (Netherlands) Long Term Biochemical and Survival Outcome of 921 Patients Treated with I-125 Permanent Prostate Brachytherapy. Int J Radiat Oncol Biol Phys 2010; 76(5):1433-1438. 106. Hsu, C et al . Comparing Results After Surgery in Patients with Clinical Unilateral T3a Prostate Cnacer Treated with or without neoadjuvent Androgen-Deprivation Therapy . BJU Int 2006;99:311-314. 107. Roehl, K et al. Cancer Progression and Survival Rates Following Anatomical Radical Prostatectomy in 3,478 Consecutive Patients: Long Term Results. J Urology 2004;172:910-914. 108. Merrick, G et al. Prostate Cancer Death is Unlikely in High Risk Patients Following Quality Permanent Seed Implantation. BJU Int 2010;107:226-233. (No ADT) 109. Merrick, G et al. Prostate Cancer Death is Unlikely in High Risk Patients Following Quality Permanent Seed Implantation. BJU Int 2010;107:226-233. (Plus ADT)
  • 1 st Group References: 1. Bahn, D et al. Targeted Cryoablation of the Prostate:7-year Outcomes in the Primary Treatment of Prostate Cancer. Urology 2002;60(Supp 2A):3-11. 2. Burri, R et al. Young Men have Equivalent Biochemical Outcomes Compared with Older Men After Treatment with Brachytherapy for Prostate Cancer. Int J Radiat Oncol Bio Phys 2010;77(5):1315-21. 3. (Open) 4. Bittner, N et al. Primary Causes of Death After Permanent Prostate Brachytherapy. Int J Radiat Oncol Bio Phys 2008;72(2):433-440. 5. Boorjian, S et al. Mayo Clinic Validation of the D'Amico Risk Group Classification for Predicting Survival Following Radical Prostatectomy. J Urology 2008;179:1354-1361. 6. Carver, B et al. Long Term Outcome following Radical Prostatectomy in Men with Clinical T3 Prostate Cancer. J Urology 2006;176:564-568. 7. Cohen, J et al. Ten-Year Biochemical Disease Control in Patients with Prostate Cancer Treated with Cryosurgery as Primary Therapy. Urology 2008;71(3):515-518. 8. Critz, F et al. 10-year Disease Survival Rates After Simultaneous Irradiation for Prostate Cancer with a Focus on Calculation Methodology. J Urology 2004;172:2232-2238. 9. Galalae, R et al. Long-term Outcome by Risk Factors Using Conformal High-Dose-Rate Brachytherapy (HDR-BT) Boost with or without Neoadjuvant Androgen Suppression for Localized Prostate Cancer . Int J Radiat Oncol Bio Phys 2004;58(4):1048-1055. 10. Kollmeier, M et al. Biochemical Outcomes After Prostate Brachytherapy with 5-year Minimal follow-up: Importance of patient Selection and implant Quality. Int J Radiat Oncol Bio Phys 2003;57(3):645-653. 11. Kuban, D et al. Long-Term Multi-Institutional Analysis of Stage T1-T2 Prostate Cancer Treated with Radiotherapy in the PSA Era. Int J Radiat Oncol Biol Phys 2003;57(4):915-928.(PSA:4-10,GS:2-6,>70 Gy) 12. Kuban, D et al. Long-Term Results of the MD Anderson Randomized Dose-Escalation Trial for Prostate Cancer. Int J Radiat Oncol Bio Phys 2008;70(1):67-74. 13. (Open) 14. (Open) 15. Loeb, S et al. Intermediate-term potency, continence & survival outcomes of radical prostatectomy for clinically high-risk or locally advanced prostate cancer . Urology 2007;69(6):1170-1175. 16. Merrick, G et al. A ndrogen deprivation therapy does not impact cause specific overall survival after permanent prostate brachytherapy. Int J Radiat Oncol Bio Phys 2006;65(3):669-77. (EBRT, Seeds, ADT) 17. Merrick, G et al. Androgen deprivation therapy does not impact cause specific overall survival after permanent prostate brachytherapy. Int j Radiat Oncol Bio Phys 2006;65(3):669-77. (EBRT & Seeds) 18. Merrick, G et al. Prognostic Significance of Perineural Invasion on Biochemical Progression-free Survival after Prostate Brachytherapy . Urology 2005;66(5):1048-1053. 19. Merrick, G et al. Impact of Supplemental External Beam Radiotherapy and/or Androgen Deprivation Therapy on Biochemical Outcome After Permanent Prostate Brachytherapy. Int J Radiat Oncol Bio Phys 2005;61(1):32-43. (EBRT & Seeds) 20. Merrick, G et al. Impact of Supplemental External Beam Radiotherapy and/or Androgen Deprivation Therapy on Biochemical Outcome After Permanent Prostate Brachytherapy. Int J Radiat Oncol Bio Phys 2005;61(1):32-43. (EBRT, Seeds, ADT) 21. Mian, B et al . Outcome of Patients w/ Gleason score 8 or Higher Prostate Cancer following Radical Prostatectomy alone . J Urology 2002;167:1675-1680. 22. Pellizzon, A et al . The Relationship Between the Biochemical Control Outcomes and the Quality of Planning of HDR as a Boost to External Beam Radiotherapy for locally and locally advanced Prostate Cancer using the RTOG-ASTRO Phoenix definition. Int J Med Sci 2008;5:113-120. 23. Stokes, S et al. Comparison of biochemical disease-free survival of patients with localized carcinoma of the prostate undergoing radical prostatectomy, transperineal ultrasound-guided radioactive seed implantation, or definitive external beam irradiation Int J Radiat Oncol Bio Phys 2000;47(1):129-136. (EBRT) 24. Potters, L et al. 12-Year Outcomes Following Permanent Prostate Brachytherapy in Patients With Clinically Localized Prostate Cancer. J Urology 2005;173:1562-1566. 25. Stokes, S et al. Comparison of biochemical disease-free survival of patients with localized carcinoma of the prostate undergoing radical prostatectomy, transperineal ultrasound-guided radioactive seed implantation, or definitive external beam irradiation Int J Radiat Oncol Bio Phys 2000;47(1):129-136. (RP) 26. Sylvester, J et al. Ten Year Biochemical Relapse Free Survival After External Beam Radiation and Brachytherapy for Localized Prostate Cancer: The Seattle Experience. Int J Radiat Oncol Bio Phys 2003;57(4):944-952. 27. (Open) 28. (Open) 29. Thames, H et al. Increasing External Beam Dose for T1-T2 Prostate Cancer: Effect on Risk Groups. Int J Radiat Oncol Bio Phys 2006; 65(4):975-981. 30. Ward, J et al. Radical Prostatectomy for Clinically Advanced (cT3) Prostate Cancer since the advent of PSA testing: 15 year outcome. BJU Int 2005; 95:751-6. 31. Zelefsky, M et al. Multi-Institutional Analysis of Long-Term Outcome for T1-T2 Prostate Cancer Treated with Permanent Seed Implantation. Int J Radiat Oncol Bio Phys 2007;67(2):327-333. 32. Zelefsky, M et al. Long Term Outcome of High Dose Intensity Modulated Radiation Therapy for Patients With Clinically Localized Prostate Cancer. J Urology 2006;176:1415-19. (81 Gy) 33. Zelefsky, M et al. Long-term Results of Conformal Radiotherapy for prostate Cancer: Impact of Dose Escalation in Biochemical Tumor control and distant Metastases-free Survival Outcomes. Int j Radiat Oncol Bio Phys 2008;71(4):1028-33. (81 Gy) 34. Zelefsky, M et al. Long-term Results of Conformal Radiotherapy for prostate Cancer: Impact of Dose Escalation in Biochemical Tumor Control and distant Metastases-free Survival Outcomes. Int j Radiat Oncol bio Phys 2008;71(4):1028-33. (86 Gy) 35. Zelefsky, M et al. High Dose Radiation Delivered by Intensity Modulated Conformal Radiotherapy Improves the Outcome of Localized Prostate Cancer. J Urology 2001;166:876-881. (75 Gy) 36. Zelefsky, M et al. High Dose Radiation Delivered by Intensity Modulated Conformal Radiotherapy Improves the Outcome of Localized Prostate Cancer. J Urology 2001;166:876-881. (81 Gy) 37. Dattoli, M et al. Long-term Outcomes After Treatment with Brachytherapy and Supplemental Conformal Radiation for Prostate Cancer Patients Having Intermediate and High-Risk Features. Cancer 2007;110(3):551-555. 38. Moyad, M et al. Statins, especially Atorvastatin, may Favorable Influence Clinical Presentation and Biochemical Progression-free Survival after Brachytherapy for Clinically Localized Prostate Cancer. Urology 2005;66(6):1150-1154. 39. Zelefsky, M et al . Long Term Outcome Following Three dimensional Conformal/IMRT for Clinical Stage T3 Prostate Cancer. Eurr Urol 2008; 53:1172-79. 40. (Open) 41. Galalae R et al. Hypofractionated Conformal HDR Brachytherapy in Hormone Naïve Men with Localized Prostate Cancer . Strahlenther Onkol 2006;182(3):135-141. 42. Demanes, DJ et al. Excellent Results from High Dose Rate Brachytherapy and External Beam Radiation Therapy for Prostate Cancer are Not Imroved by Androgen Deprivation. Amer J Clin Oncol 2009;32(4):342-347. 43. Stock, R et al. Outcomes for patients with High-Grade Prostate Cancer Treated with a Combination of Brachytherapy, EBRT and Hormone therapy. BJU Int 2009;104:1631-1636. 44. Stone, N et al . Local Control following Permanent Prostate Brachytherapy: Effect of High Biologically Effective Dose on Biopsy Results and Oncologic Outcomes. Int J Radiat Oncol Bio Phys 2010;7 6(2):355-360. 45. Bittner, N et al. Whole Pelvis Radiotherapy in Combination with Interstitial Brachytherapy: Does Coverage of the Pelvic Lymph Nodes Improve Treatment Outcome in High Risk Prostate Cancer? Int J Radiat Oncol Bio Phys 2010;76(4):1078-1084. 46. Rubio-Briones, J et al . Metastatic Progression, Cancer Specific Mortality and Need for Secondary Treatments in Patients with Clinically High Risk Prostate Cancer Treated Initially with Radical Prostatectomy. Actas Urologicas Esanolas 2010; 34(7):610-617. 47. Dattoli, M et al . Long Term Outcomes for Patients with Prostate Cancer Having Intermediate and High Risk Disease, Treated with Combination External Beam Irradiation and Brachytherapy. J Oncology 2010;2010(Article Id 471375):6 pages. 48. Menon, M et al . Biochemical Recurrence Following Robot Assisted Radical Prostatectomy: Analysis of 1384 patients with a median 5 year follow-up. Eurr Urol 2010;58:838-46. 49. Pierorazio, P et al. Long Term Survival after Radical Prostatectomy for Men with High Gleason Sum in Pathologic Specimen. Urology 2010;76(3):715-21. 100. (Open) 101. Deger, S et al . (Germany) High Dose Rate (HDR) Brachytherapy with Conformal Radiation Therapy for Localized Prostate Cancer. Eurr Urology 2005;47:441-448. 102. Magheli A et al . (Johns Hopkins) Importance of Tumor Location in Patients with High Preoperative PSA Levels ( greater than 20 ng/ml treated with Radical Prostatectomy . J Urology 2007;178:1311-15. 103. Kupelian P, et al. Improved Biochemical Relapse-Free Survival With Increased Radiation Doses in Patients With Localized Prostate Cancer: The Combined Experience of Nine Institutions in 1994 and 1995. Int J Radiat Oncol Bio Phys 2005;61(2):415-419. 104. Sylvester, J et al. 15-Year Biochemical Relapse Free Survival in Clinical Stage T1-T3 Prostate Cancer Following Combined External Beam Radiotherapy and Brachytherapy: Seattle Experience. Int J Radiat Oncol Bio Phys 2007;67(1):57-64. 105. Hinnen, K et al. (Netherlands) Long Term Biochemical and Survival Outcome of 921 Patients Treated with I-125 Permanent Prostate Brachytherapy. Int J Radiat Oncol Biol Phys 2010; 76(5):1433-1438. 106. Hsu, C et al . Comparing Results After Surgery in Patients with Clinical Unilateral T3a Prostate Cnacer Treated with or without neoadjuvent Androgen-Deprivation Therapy . BJU Int 2006;99:311-314. 107. Roehl, K et al. Cancer Progression and Survival Rates Following Anatomical Radical Prostatectomy in 3,478 Consecutive Patients: Long Term Results. J Urology 2004;172:910-914. 108. Merrick, G et al. Prostate Cancer Death is Unlikely in High Risk Patients Following Quality Permanent Seed Implantation. BJU Int 2010;107:226-233. (No ADT) 109. Merrick, G et al. Prostate Cancer Death is Unlikely in High Risk Patients Following Quality Permanent Seed Implantation. BJU Int 2010;107:226-233. (Plus ADT) 2 nd Group References: 50. Aizer A, et al. Radical Prostatectomy vs Intensity-Modulated Radiation Therapy in the Management of Localized Prostate Adenocarcinoma. Radiotherapy and Oncology 2009;93:185-191. 51. Battermann J , et al . Results of permanent prostate brachytherapy, 13 years of experience at a single institution. Radiotherapy & Oncology 2004;71:23-28. 52. Berglund R, et al. Limited Pelvic Lymph Node Dissection at the Time of Radical Prostatectomy Does Not Affect 5-Year Failure Rates for Low, Intermediate and High Risk Prostate Cancer: Results From CaPSURE. J Urology 2007;177:526-530. 53. Beyer D, et al. Relative influence of gleason score and pretreatment PSA in predicting survival following brachytherapy for prostate cancer . Brachytherapy 2003;2:77-84. 54. Cahlon O, et al. Ultra high dose (86.4Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes. Int J Radiat Oncol Bio Phys 2008;71(2):330-337. 55. Copp H, et al. Tumor Control Outcomes of Patients Treated With Trimodality Therapy For Locally Advanced Prostate Cancer . Urology 2005;65(6):1146-1151. 56. Crouzet S , et al . Multicentric Oncologic Outcomes of High-Intensity Focused Ultrasound for Localized Prostate Cancer in 803 patients. Eurr Urol 2010;58:559-566. 57. Demanes D, et al. High-Dose-Rate Intensity Modulated Brachytherapy With External Beam Radiotherapy for Prostate Cancer: California Endocurietherapy's 10-Year Results. Int J Radiat Oncol Bio Phys 2005;61(5):1306-1316. 58. Donohue J, et al. Poorly Differentiated Prostate Cancer Treated With Radical Prostatectomy: Long-Term Outcome and Incidence of Pathological Downgrading. J Urology 2006;176(3):991-995. 59. Ellis R, et al. Biochemical disease free survival rates following definitive low-dose-rate prostate brachytherapy with dose escalation to biologic target volumes identified with SPECT/CT capromab pendetide. Brachytherapy 2007;6:16-25. 60. Freedland S, et al. Radical Prostatectomy for Clinical Stage T3a Disease . Cancer 2007;109(7):1273-1278. 61. Henry A, et al. Outcomes Following Iodine-125 Monotherapy for localized Prostate Cancer: The results of Leeds 10-year single-center brachytherapy experience . Int J Radiat Oncol Bio Phys 2010;76(1):50-56. 62. Hernandez D, et al . Contemporary Evaluation of the D’Amico risk classification of Prostate Cancer. J Urol 2007;70(5):931-935. 63. Hong S, et al . Predictions of Outcomes after Radical Prostatectomy in Patients Diagnosed with Prostate Cancer of Biopsy GS > 8 via Contemporary multi ( > 12)-core prostate biopsy. BJU Int 2011;108(2):217-222. 64. Hull G, et al. Cancer control with radical prostatectomy alone in 1000 consecutive patients. J Urology 2002;167:528-534. 65. Khaksar S, et al. Interstitial low dose rate brachytherapy for prostate cancer-a focus on intermediate & high risk disease. Clinical Oncology 2006;18:513-518. 66. Khuntia D, et al. Recurrence-free survival rates after external-beam radiotherapy for patients with clinical T1-T3 prostate carcinoma in prostate specific antigen era . Cancer 2004;100(6):1283-1292. 67. Koontz B, et al. Morbidity and Prostate Specific Antigen Control of External Beam Radiation Therapy plus Low Dose Rate Brachytherapy Boost for Low ,Intermediate and High Risk Prostate Cancer. Brachytherapy 2009;8:191-196. 68. Kupelian P , et al . Hypofractionated Intensity-Modulated Radiotherapy (70Gy at 2.5Gy per fraction) for Localized Prostate Cancer: Cleveland Clinic Experience. Int J Radiat Oncol Bio Phys 2007; 68(5):1424-1430. 69. Kwok Y, et al. Risk Group stratification in patients undergoing permanent I-125 prostate brachytherapy as monotherapy. Int J Radiat Oncol Bio Phys 2002;53(3):588-594. 70. Lederman G, et al. Retrospective Stratification of a Consecutive Cohort of Prostate Cancer Patients Treated with a Combined Regimen of External-beam Radiotherapy and Brachytherapy. Int J Radiat Oncol Bio Phys 2001;49(5):1297-1303. 71. Lee L, et al. Role of Hormonal therapy in the management of intermediate to high risk prostate cancer treated with permanent radioactive seed implantation. Int J Radiat Oncol Bio Phys 2002;52(2):444-452. 72. Liauw S, et al. Dose-escalated radiotherapy for hight-risk prostate cancer: outcomes in modern ear with short termandrogen deprivation therapy. Int J Radiat Oncol Bio Phys 2010;77(1):125-130. 73. Livsey J, et al. Hypofractionated Conformal Radiotherapy in Carcinoma of the Prostate: five-Year Outcome Analysis. Int J Radiat Oncol Bio Phys 2003;57(5):1254-1259. 74. Nobes J, et al. Biochemical Relapse-Free Survival in 400 Patients Treated with I-125 Prostate Brachytherapy: the Guildford Experience. Prostate Ca & Prostatic Disease 2009;12:61-66. 75. Phan T, et al. High dose rate brachytherapy as a boost for the treatment of localized prostate cancer. J Urology 2007;177:123-127. Prada P, et al. High-dose-rate intensity modulated brachytherapy with external-beam radiotherapy improves local and biochemical control in patients with high risk prostate cancer. Clin Transl Oncol 2008;10:415-421. Sathya J, et al. Randomized Trial comparing Iridium implants plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol 2005;23(5):1192-1199. Stock, R. et al. Combined Modality Treatment in the Management of High Risk Prostate Cancer . Int J Radiat Oncol Bio Phys 2004;59(5):1352-1359. Stone N, et al. Multicenter Analysis of Effect of High Biologic Effective dose on Biochemical Failure and Survival Outcomes in Patients with Gleason 7-10 Prostate cancer Treated with Permanent Prostate Bracyhhterapy. Int J Radiat Oncol Bio Phys 2009;73(2):341-346. Stone N, et al. Customized dose Prescription for Permanent Prostate Brachytherapy: Insights From a Multicenter Analysis of Dosimetry Outcomes. Int J Radiat Oncol Bio Phys 2007;69(5):1472-1477. Yamada Y, et al. Favorable Clinical Outcomes of 3-D Computer Optimized High Dose Rate Prostate Brachytherapy in the management of Localized Prostate cancer. Brachytherapy 2006;5:157-164. Yossepowitch O, et al . Radical Prostatectomy for Clinically Localized High Risk Prostate Cancer: Critical Analysis of Risk Assessment Methods. J Urology 2007;178:493-499. (Def. #1) Yossepowitch O, et al . Radical Prostatectomy for Clinically Localized High Risk Prostate Cancer: Critical Analysis of Risk Assessment Methods. J Urology 2007;178:493-499. (Def. #2) Yossepowitch O, et al . Radical Prostatectomy for Clinically Localized High Risk Prostate Cancer: Critical Analysis of Risk Assessment Methods. J Urology 2007;178:493-499. (Def. #3) Zwahlen D , et al. High Dose Rate Brachytherapy in Combination with Conformal External Beam Radiotherapy in the Treatment of Prostate Cancer. Brachytherapy 2010;9:27-35. D’Amico A, et al. Biochemical outcomes after Radical Prostatectomy or External Beam Radiation Therapy for patients with clinically localized prostate carcinoma in the Prostate Specific Antigen Era. Cancer 2002;95(2):281-286. (RP) D’Amico A, et al. Biochemical outcomes after Radical Prostatectomy or External Beam Radiation Therapy for patients with clinically localized prostate carcinoma in the Prostate Specific Antigen Era. Cancer 2002;95(2):281-286. (EBRT) Stokes S, et al. Comparison of biochemical disease-free survival of patients with localized carcinoma of the prostate undergoing radical prostatectomy, transperineal ultrasound-guided radioactive seed implantation, or definitive external beam irradiation. Int J Radiat Oncol Bio Phys 2000;47(1):129-136. (seeds) Yossepowitch O, et al . Radical Prostatectomy for Clinically Localized High Risk Prostate Cancer: Critical Analysis of Risk Assessment Methods. J Urology 2007;178:493-499. (Def. #4)
  • Transcript

    • 1. John Blasko MD Seattle, WA
    • 2. Definition: High-RiskStandard definition of High-Risk (any one of the below) PSA > 20 Gleason > 7 Stage > T2b Two or three Intermediate-Risk FactorsAn even more serious form of High-Risk: Any Gleason grade 5 (Gleason score 9 or 10) Seminal vesicle invasion Pelvic lymph node metastases
    • 3. High Risk Group is HeterogeneousBig difference between a T1c, Gleason 8, PSA 6 and a T3, Gleason 7, PSA 40.The differing profile of High Risk disease in research studies is highly era dependant and continues to be a problem in comparing treatment outcomes today.Trend for High Risk category today is lower volume disease but high grade
    • 4. High RiskApproximately 15% of the 220,000 men who are diagnosed annually (33,000 men) are High-RiskCancer specific mortality at 10 years for High-Risk disease averages between 5% and 15%There is some consensus among experts about treatment: 1. Treat, don’t observe (except the very elderly or infirm) 2. Radiation plus testosterone inactivating pharmaceuticals (TIP) is generally a better treatment than surgery (except perhaps in men who have a high Gleason but very low volume disease)
    • 5. Staging Studies: High RiskConsidered standard: Bone Scan to evaluate for possible bone metastasis CT scan (or MRI ) of abdomen and pelvis to evaluate for possible pelvic node metastasesLogical but still not considered standard: Endorectal MRI to evaluate for possible seminal vesicle invasion (scan quality varies depending on equipment and physician experience )
    • 6. What to Do with Scan Results that Are Considered Ambiguous?Suspicious bone scan findings can be further evaluated with MRI or with CT directed biopsySuspicious pelvic node findings can be evaluated with ProstaScint, experimental PET scans, CT directed needle biopsy or laparoscopic surgerySuspicious endorectal MRI findings suggesting seminal vesicle invasion can be evaluated with color doppler or endorectal MRI directed biopsy
    • 7. Surgery for Gleason 8-10? Epstein, Urology 76:715, 20109300 men with median: PSA of 7.5 and stage T280% recurrence rate at 15 years70% had extra capsular diseaseAn even worse outcome was associated with any: Gleason grade 5 Seminal vesicle invasion Positive lymph nodesTake home message: Surgical cure rates are low withhigh Gleason score when there is a palpableabnormality on digital rectal examination
    • 8. 5-Year Surgery Relapse Rates for High-Risk # Patients % Relapsed Reference 110 55% Nguyen, J Urol 181:75, 2009 206 48% Yossepowitch, J Urol 178:493, 2007 957 32% Spahn, EurUrol 58:1 2010 712 35% Ward, BJU 95:751, 2005 1179 53% Matti, Eur Urol 53:118, 2008 188 29% Zwergel, Eur Urol 52: 1058, 2007 42% Average Relapse Rate @ 5 years
    • 9. Outcome after Surgery in Men with High-Risk is Improved with TIPMen with High-Risk: Two years of TIP consisting of Zoladex plus Casodex resulted in surprisingly low relapse rate in 481 men with High-Risk disease (Dorff, JCO 29:2040, 2011) Relapse rate @ five years was only 7.5%Men with Positive Nodes: Immediate TIP was better than TIP started at relapse in men with positive nodes at surgery (Messing, NEJM, 341:1781, 1999) Mortality @ 7 years: 15% vs. 40%
    • 10. Pelvic XRT after Surgery in MenFound Node Positive from Surgery Briganti, Eur Urol 2011364 men node positive after surgery 117 men had TIP plus pelvic radiation vs. 247 men had TIP without radiation10-year cancer specific survival 86% with TIP plus XRT to pelvic nodes 70% with TIP alone
    • 11. Is Surgery Appropriate for High Risk? Please consider the following: If cure rates with surgery alone are poor… If men do better after surgery with the addition of TIP…. If men do better after surgery with pelvic node radiation….. Why not proceed straight to radiation and skip the surgery ?
    • 12. Surgery Vs. Radiation for High-Risk Arcangeli, IJROBP 75:975, 2009162 men treated with EBRT plus TIP 9 months of testosterone deprivation started 2 months before xrt 80 gy without node treatment122 men treated with radical prostatectomyRadiation patients had higher Gleason scores and clinical stage that surgery patients3-year relapse rate was 13% for the radiation patients and 30% for the surgery patients
    • 13. Rationale for seed implant boostHigher dose, more conformal radiation treatment is attained with seed implant compared to external beam radiation aloneStudies incorporating seed implant boost show excellent relapse free survival rates
    • 14. Sculpting Radiation Doses with Seeds
    • 15. Radiation Dose From Seeds in EBRT Equivalent Doses ProstateTypical IMRT ≈ 100 Gy EBRT high dose equivalent78 – 81 Gy Area of Prostate Receiving 150+ Gy EBRT equivalent
    • 16. Seeds + EBRT Dose vs. Risk Grouping Low Risk Disease High Risk Disease (standard) (seeds + EBRT) (inadequate) (standard for seeds alone) 552 patients 2,188 patients p < 0.0001 (inadequate)Achieving high dose more important for *Stone NN et al, IJROBPHigh Risk disease than for Low risk Vol. 69, #5, 1472, 2007
    • 17. Cure Rates: Seeds for High-Risk # TIP Cure Follow ReferencePts. Rate Up190 6 mo. 95% 8 yr. Merrick, IJROBP 61:32, 2005243 ½ 6 m0. 88% 10 yr. Bittner, IJROBP 72:433, 2008107 no 63% 10 yr Demanes, AJCO 32:342, 2009
    • 18. Very High Risk Treated with Seeds + EBRT + TIP*131 patients, median age 68 yr.  T3  PSA > 40  Gleason 10  Gleason 8-9 with >50% + bx cores,  Gleason 8-9 with PSA > 2012 year results  Overall survival 61%  Cause-specific survival 88%  PSA progression free 71%Cause of death  Prostate cancer 8.3%  Heart disease 22.2% *Bittner N, Merrick GS, Butler WM, et al. Brachytherapy 11(2012) 250-255
    • 19. Relapse Rates: High-Risk EBRT, Seeds & ADT 20 20 16 16 45 45 109 109 Brachy 19 18 19 18 4 4 38 22 22 108 108 EBRT & ADT 17 EBRT & SeedsTreatment Success 43 32 43 32 37 37 34 34 44 47 47 Hypo EBRT 44 9 41 9 41 22 104 48 104 36 36 48 10 10 42 11 12 42 24 12 8 24 25 25 8 101 101 106 106 33 21 33 21 5 5 39 39 EBRT 103 103 35 35 11 11 7 6 26 7 6 26 Surgery 31 30 Protons 46 31 30 46 107 107 102 15 102 15 HDR 105 105 EBRT Seeds + r g or P AS P % 23 29 29 ← Years from 23 Treatment 49 49 ADT → Robot RP • Prostate Cancer Results Study Group • Numbers within symbols refer to references 19 Prostate Cancer Center of Seattle
    • 20. Relapse Rates: High-Risk >40 months follow-up or less than 100 patients 65 81 20 20 16 16 45 109 109 Brachy 19 18 45 80 19 18 4 74 4 108 108 EBRT & ADT 78 38 22 22 67 67 17 55 75 EBRT & Seeds 72 54 85 43 76 43 37 37 72 54 34 34 44 32 32 47 47 Hypo EBRT 66 9 41 66 9 41 68 44 2 57 104 71 6436 68 71 6436 79 48 59 48 59 2 10 104 10 42 42 50 50 56 11 56 12 12 24 24 53 25 8 61 8 61 25 89 89 101 101 EBRT 62 106 62 106 70 70 33 21 33 21 5 39 5 39 11 11 60 60 103 103 83 7 82 26 83 7 82 26 35 35 63 66 Protonsss ecc uS t ne maer T 52 63 52 84 84 73 31 30 58 77 46 73 46 31 30 58 88 88 86 87 86 87 107 107 102 15 102 15 HDR t 51 51 105 105 EBRT Seeds + r g or P AS P % 23 29 Surgery 29 ← Years from 23 Treatment 69 69 49 49 ADT → Robot RP • Prostate Cancer Results Study Group HIFU • Numbers within symbols refer to references 02/23/13 20 Prostate Cancer Center of Seattle
    • 21. Rationale for Pelvic RadiationMetastatic disease represents the most dangerous component of the cancerHistorically, pelvic radiation is incorporated as standard in all randomized prospective trials of High-Risk diseaseOne randomized study by Mack Roach showed improved disease free survival at 5 years with pelvic xrtAnother randomized study by Pascal Pommier showed no benefitModern IMRT radiation is far less toxic that older radiation technology
    • 22. Hormones Plus Node Radiation Roach, IJROBP 69:646, 20071500 patients randomized between no node radiation and 50 Gy of node radiation. Dose to prostate was 70 Gy. Men were also randomized between TIP starting two months before radiation and continuing for four months vs. starting TIP at the end of radiation (also for four months)Patients: Median PSA was 22, 73% of men had Gleason 7 or more, 2/3 of men were stage T2c, T3 or T4Conclusion: Node radiation improved cure rates. However, the improvement was only seen when TIP was started 2 months before radiation
    • 23. Pelvic Node Radiation Ineffective? Pommier, JCO 25:5366, 2007444 patientsPelvic node radiation 46 Gy (instead of 50Gy)Small radiation field than the Roach studyInitial dose to prostate only 66 Gy50% of study participants had calculated risk of node metastases of less than 15%Patients: Median PSA 16, 50% Gleason 6 or less, 25% stage T3 (the rest were T1 or T2)Conclusion: No difference in cure rates at 5 years but study was seriously underpowered to detect a difference
    • 24. Toxicity from Node Radiation?Deville, IJROBP 78:763, 2010 30 patients treated with IMRT 79 Gy 30 patient treated IMRT 79 Gy and 45 Gy to pelvis At 24 months no “late” GI or GU toxicityDeville, IJROBP 82:1389, 2012 31 patients IMRT 70.2 Gy (to fossa after surgery) 36 patients IMRT 70.2 to fossa & 45 Gy to pelvis No significant difference in “late” toxicity at 25 months
    • 25. Calculating Risk of Nodes Yu, IJROBP 80:69, 2011Mack Roach has proposed that only men with more than a 15% risk of node metastases should be considered candidates for node radiationThe % risk of nodes involvement can be calculated as: (Gleason score minus 5) x (PSA/3 +1.5 x T stage) where T = 0, 1 or 2 for T1c, T2a, and T2b or T2c.This is the so called Yale formula which has supplanted the Roach formula and the Nguyen formula due to enhanced accuracyNote: Formula does not incorporate other important prognostic info such as % biopsy or imaging results
    • 26. Not All Node Radiation Equal Lawton, IJROBP 74:377, 2009Two different clinical cases distributed to 14 radiation oncologists with expertise in genitourinary oncologyConclusion, “Significant disagreement exists in the definition of…. pelvic nodal radiation therapy among GU radiation oncology specialists”Consensus meeting October 2007 to develop a clinical target volume (CTV) for node radiation by 10 GU radiation specialists.Access to their conclusions was published in the same journal (Lawton, IJROB 74:383, 2009)
    • 27. Longer Duration of TIP is Clearly Better1. 4 months Zoladex/Flutamide vs. none (Pilepich, IJROBP 50:1243, 2001)  Cancer death @ 8 years: 23% vs. 31%2. 36 months of Zoladex vs. none (Bolla, Lancet 2010)  Cancer death @ 10 years: 10% vs. 30%3. 24 months of Zoladex vs. 4 months of Zoladex plus Flutamide: (Horwitz, JCO 26:2497, 2008)  Cancer death @ 10 years: 11% vs. 16%
    • 28. Rationale for Casodex or Flutamide Nanda, IJROBP 76: 1439,2010628 High-Risk men treated with:  Beam radiation  Brachytherapy boost  Average of 4 months hormone blockade401 men received Lupron alone whereas 227 men were treated with a combination of Lupron plus antiandrogenOutcome at 5 years: Men receiving Lupron plus antiandrogen had a significantly lower rate of prostate cancer mortality
    • 29. Adjuvant ChemotherapyRationale: Treat micro-metastatic disease while still vulnerable to eradicationProven benefit in other tumor types such as breast, colon and lung cancerChemotherapy options limited to two drugs: Taxotere or MitoxantronePreliminary trials in prostate cancer suggest a possible benefit
    • 30. Adjuvant Mitoxantrone Wang, BJU 86:675, 200038 men with locally advanced diseaseAll given with Lupron / Flutamide indefinitely19 men randomly allocated to 4 cycles of mitoxantrone (this is the only randomized trial of adjuvant chemotherapy in existance)Kaplan-Meier survival curve shows significantly prolonged survival in the men administered mitoxantrone (next slide)
    • 31. MitoxantroneNo Mitoxantrone
    • 32. Adjuvant Taxotere Kibel, J Urol 177:1777, 200777 men treated with surgery most who had seminal vesicle invasion and high Gleason scoresThe median time to relapse for this group of patients based on their stage, Gleason score and PSA was predicted to be 10 months by a Kattan NomogramAll 77 men were administered weekly Taxotere for 6 mo.Actual median time to relapse was improved by 50% (to 15.7 months)
    • 33. Radiation + Hormones + Taxotere DiBiase IJROP 81:732,201142 patients 75 % grade 4 + 3 or higher Median PSA 17.8Treatment Pelvic radiation Brachytherapy boost Lupron for two years Weekly Taxotere for 3 monthsOutcome: 70% disease free after 7 years
    • 34. Conclusion: The Best Treatment for High-Risk is Multimodality TherapyTIP for two years, to be started a couple months before XRTIMRT to prostate and pelvic nodes when calculated risk of nodes is > 15%Seed implant boost to prostate Palladium or Iodine permanent seeds HDR temporary seeds (for SV invasion?)Adjuvant chemotherapy is still considered investigational

    ×